NASDAQ: MLTX

MoonLake Immunotherapeutics

Healthcare | Biotechnology

No licensed closing price on file for MLTX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

MoonLake Immunotherapeutics (NASDAQ: MLTX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 01:49 UTC.

What MoonLake Immunotherapeutics does

Moonlake Immunotherapeutics is a clinical stage biotechnology company developing SLK, a novel tri-specific Nanobody that inhibits IL-17A and IL-17F, exclusively licensed from MHKDG. Nanobodies are small molecules that bind selectively to specific antigens with high affinity and offer potential advantages over traditional antibodies, including better tissue penetration and easier manufacturing.

Summarized from MoonLake Immunotherapeutics’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Charts

Charts are in the appInteractive charts for MLTX are available in Oxford Ledge.
Open MLTX in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-07-29

2026-07-29Chief Scientific OfficerSale-1,100$22.0K
2026-07-23Chief Scientific OfficerSale-2,448$49.0K
2026-07-23Chief Scientific OfficerSale-50,000$1.00M

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

BVF INC/IL16,001,284$311.54M0.0%
Deep Track Capital, LP6,999,025$136.27M+9.2%
D. E. Shaw & Co., Inc.3,365,507$65.53M+40.8%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2026-02-23Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersJorge SantosEstimatedSEC 8-K →
2024-12-18Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersKara LassenEstimatedSEC 8-K →
2021-05-03Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

MoonLake Immunotherapeutics submits sonelokimab BLA
Seeking Alpha Markets2026-09-30
MoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy
Seeking Alpha Feed2026-09-08
STAT+: Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate?
STAT News2026-08-11
MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day - Slideshow
Seeking Alpha Feed2026-06-22
MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript
seekingalpha.com2026-06-22

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for MLTX and 5,000+ tickers.

Create a free account — keep MLTX

For your agent

GET /api/data?ticker=MLTX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt